Showing results (191-200 of 380) with videos related to

Sort By:
Pageof 38
Tumori|December 23, 1998
Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare TumorsS Bretti, A Berruti, L Dogliotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2001
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patientsM Venturini, A Michelotti, P Papaldo, et al.
Frontiers in Endocrinology|March 29, 2021
Psychotropic Drugs Levels in Seminal Fluid: A New Therapeutic Drug Monitoring Analysis?Rossella Mazzilli, Martina Curto, Donatella De Bernardini, et al.
British Journal of Cancer|January 1, 1995
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task ForceA Ardizzoni, G F Addamo, E Baldini, et al.
Frontiers in Pharmacology|May 17, 2017
Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?Francesco Fazio, Albino Carrizzo, Luana Lionetto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo GroupL Del Mastro, M Venturini, R Lionetto, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2013
L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptorsCarla Nasca, Dionysios Xenos, Ylenia Barone, et al.
Annals of Surgical Oncology|May 26, 1999
Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori GroupP Queirolo, M Ponte, M Gipponi, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|January 9, 2017
The metabolite beta-aminoisobutyric acid and physical inactivity among hemodialysis patientsAlessio Molfino, Maria Ida Amabile, Thomas Ammann, et al.
Expert Opinion on Emerging Drugs|August 7, 2012
Emerging treatment for chronic migraine and refractory chronic migraineLuana Lionetto, Andrea Negro, Stefano Palmisani, et al.
Pageof 38